Expert Aesthetics: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://erasingage.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “The following claims concerning compounded semaglutide and tirzepatide products appear on your website:”

2. 2

   “• “At home weight loss with the popular Ozempic generic Semaglutide.””

3. 3

   “• “At home weight loss with the popular Mounjaro generic Tirzepatide.””

4. 4

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

erasingage.com returned a live site on 2026-08-09 titled "Brenda Burr | Expert Aesthetics-Erasing Age | United States", running a banner reading "Celebrating 12 years of business", with a Weight Loss/Peptides section, an online store, gift cards, payment options and online booking. That is a check of whether the site is up and who it names; it is not a check of anything the letter alleges.

"The popular Ozempic generic Semaglutide" is a phrase that does three things at once, and only one of them is a claim you can argue with. It flags demand — other people are buying this. It supplies a familiar landmark — Ozempic. And in the middle it slips in the word "generic", which is the only regulated term in the sentence and the only one that is wrong: a generic is an FDA-approved copy of an approved drug, held to the original's standards, and a compounded product is not one. Wrapped in a sentence about at-home convenience it reads as a description of a category rather than an assertion about a product, which is exactly why it is worth pausing on. The other useful detail is who received the letter. FDA addressed it to a named nurse-owner at a Texas clinic that has been trading for over a decade, not to a numbered LLC behind a checkout page — a reminder that this kind of letter is about the words on a website, and that established, accountable, locally-run practices receive them too. Nothing in the letter concerns how these products were made or what was in them. FDA made no finding on quality, and has not closed the letter out.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Expert Aesthetics failed to respond.